Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis

Neurology

Volumn 64, Issue 9, 2005, Pages 1641-1643

  Ponseti, J M ^a   Azem, J ^a   Fort, J M ^a   Lopez Cano M ^a   Vilallonga, R ^a   Buera, M ^a   Cervera, C ^a   Armengol, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ANKLE EDEMA; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; ELECTROMYOGRAM; FEMALE; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NEUROPATHY; PARESTHESIA; PRIORITY JOURNAL; REMISSION; SYMPTOMATOLOGY; THYMECTOMY; TREATMENT OUTCOME; TREMOR; VERTIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ATAXIA; AUTOANTIBODIES; CYCLOSPORINE; DIZZINESS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PREDNISONE; PROSPECTIVE STUDIES; RECEPTORS, CHOLINERGIC; REMISSION INDUCTION; RENAL INSUFFICIENCY; TACROLIMUS; THYMECTOMY; TIME; TREATMENT OUTCOME;

EID: 18144429444     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000160392.32894.6D     Document Type: Article

References (10)

1. Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 2002;9:627-628.
2. Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002;25:111-114.
3. Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T, Japanese FK506 MG Study Group. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003;28:570-574.
4. Wakata N, Saito T, Tanaka S, Hirano T, Oka K. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 2003;106:5-8.
5. Kawaguchi N, Yoshiyama Y, Nemoto Y, Munataka S, Fukutake T, Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20: 1269-1273.
6. Ponseti JM, Fort JM, Espin E. Armengol M. Tacrolimus (FK506) in the treatment of prednisone-resistant myasthenia gravis. Preliminary results of 20 cases [in Spanish]. Med Clin (Barc) 2002;118:117.
7. Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005 (in press).
8. Ponseti JM. Miastenia gravis. Manual terapéutico. Barcelona: Springer-Verlag, 1995.
9. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000;55:16-23.
10. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989;143:718-726.